|
|
Article: Lorus to present results of studies with GTI-2040 in breast cancer models at the American Association for Cancer Research Special Conference; - Cooperative anti-tumor activity observed in combination with standard chemotherapy agents -.
- Article from:
- PR Newswire
- Article date:
- October 8, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Lorus Therapeutics Inc. ("Lorus") will be presenting the results of preclinical studies aimed at assessing the potential therapeutic application of GTI-2040 for the treatment of breast cancer at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Advances in Breast Cancer Research; Genetics, Biology, and Clinical Implications, which will be held in Huntington Beach, California from October 8-12, 2003.
An abstract prepared by Lorus entitled "GTI-2040, An Antisense Oligonucleotide Targeting the R2 Component of Human Ribonucleotide Reductase Displays Cooperative Anti-tumor Activity when Combined with Standard Chemotherapeutic ...
Related newspaper, magazine, and journal articles:
|
|
Article: Breast Cancer Research Stamp Funding the ...
AScribe Health News Service;
July 29, 2008 ;
700+ words
... ... against breast cancer. The Breast Cancer Research Stamp is the first postage ... that historic day, the Breast Cancer Research Stamp has raised more money ... over $63.17 million for breast cancer research to date. The stamp currently ...
|
|